Aprea Therapeutics Shifts Focus to Combination Therapies

Aprea Therapeutics ( (APRE) ) has shared an announcement.

On October 15, 2025, Aprea Therapeutics announced the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119 in its ongoing ABOYA-119 study for advanced solid tumors. The company is pausing further monotherapy enrollment to focus on combination therapies, leveraging ATRN-119’s potential synergistic effects with DNA-damaging agents. This strategic shift aims to enhance the therapeutic potential of ATRN-119, with ongoing discussions for combination studies in HPV+ head and neck cancer and other indications.

The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Spark’s Take on APRE Stock

According to Spark, TipRanks’ AI Analyst, APRE is a Underperform.

Aprea Therapeutics receives a low overall score due to significant financial challenges, including consistent losses and lack of revenue generation. The company’s strong balance sheet is a positive but is offset by negative cash flows and a reliance on external financing. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield.

To see Spark’s full report on APRE stock, click here.

More about Aprea Therapeutics

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells. Their clinical programs include APR-1051, a WEE1 kinase inhibitor, and ATRN-119, a macrocyclic ATR inhibitor, both aimed at treating solid tumor indications.

Average Trading Volume: 49,927

Technical Sentiment Signal: Sell

Current Market Cap: $8.56M

For an in-depth examination of APRE stock, go to TipRanks’ Overview page.